Skip to main content
Premium Trial:

Request an Annual Quote

MOgene Providing Services Based on Lawrence Livermore National Laboratory's Array

NEW YORK (GenomeWeb News) – Genomics service provider MOgene today said it has signed an agreement with Lawrence Livermore National Laboratory to provide services using the Lawrence Livermore Microbial Detection Array.

The array probes for more than 3,000 bacterial and viral species and has been optimized for NimbleGen arrays, said MOgene, a NimbleGen service provider. The array provides rapid and comprehensive analysis of bacteria and viruses from biological material of unknown nature, and has been shown to be of use in food and pharmaceutical safety, detection of bacterial and viral infections, animal health, and other applications, the St. Louis-based firm said.

It added that the array would allow food safety professionals, law enforcement, medical professionals, and others to detect any virus or bacteria that has been sequenced and included among the arrays' probes within 24 hours.

Shaukat Rangwala, senior vice president of MOgene, said in a statement that the deal "allows us to expand into new areas for our microarray and sequencing service business."

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.